Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma reported consolidated Q2 FY26 (ended Sep 30, 2025) revenue of Rs. 1,354 crore, up 14% YoY, with profit after tax of Rs. 260 crore, up 20% YoY. EBITDA stood at Rs. 328 crore at a 24% margin, weighed down by a Rs. 41 crore mark-to-market forex loss; excluding it, EBITDA margin would be 27%. For H1 FY26, revenue grew 14% to Rs. 2,656 crore and PAT rose 12% to Rs. 516 crore, with healthy ROCE of 30% and RONW of 25%. The Board declared a 1st interim dividend of Rs. 28 per share on a Rs. 2 face value, totalling Rs. 349.82 crore, with record date November 10, 2025. The US Generic segment surged 48% in Q2, while Africa Institution sales fell 25%. Auditor B S R & Co. LLP issued an unmodified opinion but drew attention to the August 2025 Income Tax search operations as an emphasis of matter.
Solid PAT growth and a sizeable dividend payout are positives for shareholders, but the reported EBITDA margin compression and unresolved Income Tax search overhang may cap near-term sentiment on the stock.